Hormonal
Statins are safe and effective as first-line treatment for hyperlipidemia in MASLD patients, despite under-prescription, and may reduce cardiovascular events and liver disease burden.
If you have MASLD and high cholesterol or CVD risk, ask your doctor about statins. They are safe for your liver, even if you have some liver scarring, and are the first-line treatment to lower your risk of heart disease. Do not avoid them due to fear of liver damage.
statins should be used as first-line treatment... It is important to emphasize that statins are safe to use in patients with MASLD... statins might limit the disease burden of MASLD possible through anti-lipid and anti-inflammatory effects
Why this rating
Supported by observational data, post-hoc RCT analyses, and consensus guidelines, though histological improvement data is mixed.
Source
Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
Anders Mellemkjær et al. · European Journal of Internal Medicine · 2023
DOI 10.1016/j.ejim.2023.11.012
More from this paper
- Lifestyle interventions, specifically a Mediterranean diet and 150-300 minutes of moderate or 75-150 minutes of vigorous exercise weekly, are recommended to induce weight loss and improve cardiovascular risk factors in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Good
- GLP-1 analogues (Semaglutide and Liraglutide) are recommended for MASLD patients with BMI >27 kg/m2 and CVD risk factors when lifestyle intervention is insufficient, offering significant weight loss and CVD risk reduction.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →